Myriad Genetics, AstraZeneca Expand Collaboration on Olaparib Phase 3 Clinical Trials
September 04, 2013 at 06:05 AM EDT
Myriad Genetics, Inc. (NASDAQ: MYGN ) announced today that it has entered into an expanded, nonexclusive global collaboration agreement with AstraZeneca (NYSE: AZN ) to provide companion diagnostics for the olaparib Phase 3 clinical development program. Olaparib is an investigational orally active poly-ADP ribose polymerase (PARP) inhibitor being
